Atea Pharmaceuticals, Inc. (AVIR)
| Market Cap | 250.59M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -168.39M |
| Shares Out | 85.53M |
| EPS (ttm) | -2.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 203,916 |
| Open | 3.030 |
| Previous Close | 3.020 |
| Day's Range | 2.905 - 3.030 |
| 52-Week Range | 2.750 - 4.145 |
| Beta | 0.18 |
| Analysts | Hold |
| Price Target | 6.88 (+134.81%) |
| Earnings Date | Mar 6, 2025 |
About AVIR
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorpor... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for AVIR stock is "Hold" and the 12-month stock price forecast is $6.88.
News
Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value
BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral anti...
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own approximately 5.4% of the outstanding stock of A...
Atea Pharmaceuticals Issues Statement Regarding Director Nominations
BOSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company) a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiv...
Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025
BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral anti...
Atea Pharmaceuticals, Inc. (AVIR) Q4 2024 Earnings Call Transcript
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Jonae Barnes - Senior Vice President, Investor Relations & Corporate Communicat...
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Program for Hepatitis C Virus ( HCV) Patient Enrollment in Global Phase 3 HCV Program Expected to Start in April 2025 Conference Cal...
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025
BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral ther...
Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiv...
Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral ther...
Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok, the Managing Director of JEC Capital Partners (together with their affiliates, the “Concerned Shareholder Group” or “we”), who collective...
Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships
BOSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiv...
After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study
On Wednesday, Atea Pharmaceuticals, Inc. AVIR released Phase 2 study data from the regimen of bemnifosbuvir and ruzasvir for the hepatitis C virus infection that causes liver swelling and can lead to ...
Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)
Primary Endpoint Achieved with 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) after Short Eight Week Treatment Duration
Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference
BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral ther...
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024
BOSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral ther...
Atea Pharmaceuticals, Inc. (AVIR) Q3 2024 Earnings Call Transcript
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Jonae Barnes - SVP of Investor Relations and Corporate Communications Dr. Jea...
Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Topline SVR12 Results from Global Phase 2 Hepatitis C Virus (HCV) Study (N=275) Expected Q4'24 New Data Supportive of HCV Combination to be Presented at the American Association for the Study of Liver...
Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024
BOSTON, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral ther...
Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19
BOSTON, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral the...
Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir's Metabolic Activation Pathway
New Data Further Elucidates Bemnifosbuvir's Metabolic Activation Pathway, Critical to its Mechanism of Action as an Antiviral Therapy for Treatment of COVID-19, HCV and Potentially a Broad Range of RN...
Atea Pharmaceuticals, Inc. (AVIR) Q2 2024 Earnings Call Transcript
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q2 2024 Results Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Jonae Barnes - Senior Vice President of Investor Relations and Corpora...
Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024
BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral ther...
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral thera...
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024
Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial
Atea Pharmaceuticals, Inc. (AVIR) Q1 2024 Earnings Call Transcript
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Jonae Barnes - Senior Vice President of Investor Relations and Corporate Communi...